Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

9.720 +1.640 (+20.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atara Biotherap

< Previous 1 2 3 4 5 Next >
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
From Atara Biotherapeutics
Via Business Wire
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.